Characteristics of 242 Study NSCLC Patients
| Variable | Data |
|---|---|
| TNM stage (n) | |
| I | 91 (37.6%) |
| II | 25 (10.3%) |
| III | 72 (29.8%) |
| IV | 54 (22.3%) |
| Sex (n) | |
| Female | 143 (59.1%) |
| Male | 99 (40.9%) |
| Race* (n) | |
| White | 94 (38.9%) |
| Black | 139 (57.4%) |
| Other | 9 (3.7) |
| Smoking history (n) | |
| Never | 24 (10.0%) |
| Current | 92 (38.0%) |
| Prior | 126 (52.0%) |
| Histology (n) | |
| Adenocarcinoma | 173 (71.5%) |
| Squamous cell carcinoma | 56 (23.1%) |
| NOS | 13 (5.4%) |
| Treatment (n) | |
| Surgical | 100 (41.3%) |
| Nonsurgical | 106 (43.8%) |
| None | 36 (14.9%) |
| ECOG PS (n) | |
| 0 | 58 (24%) |
| 1 | 85 (35.1%) |
| 2 | 21 (8.7%) |
| 3 | 9 (3.3%) |
| Median SD PET SUVmaxwb | 11.8 (range, 1.1–61.4) |
| Median HD PET SUVmaxwb | 17.4 (range, 1.5–82.5) |
| Mean age (y) | 68.3 (SD, 9.02) |
↵* Other race groups included 8 Asian patients and 1 Hawaiian patient.
ECOG PS = Eastern Cooperative Oncology Group performance score (not available in 69 patients); NOS = NSCLC not otherwise specified, including 10 patients with NOS, one patient with pulmonary spindle cell carcinoma, and 2 patient with solid carcinoma.